Volume | 261,291 |
|
|||||
News | - | ||||||
Day High | 7.22 | Low High |
|||||
Day Low | 7.05 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Fulcrum Therapeutics Inc | FULC | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
7.14 | 7.05 | 7.22 | 7.14 | 7.13 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
3,308 | 261,291 | $ 7.15 | $ 1,868,599 | - | 2.43 - 13.70 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:00:06 | formt | 2,843 | $ 7.14 | USD |
Fulcrum Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
440.98M | 61.94M | - | 2.81M | -97.34M | -1.57 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Fulcrum Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical FULC Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 7.00 | 7.53 | 6.67 | 7.18 | 509,468 | 0.14 | 2.00% |
1 Month | 9.46 | 9.60 | 6.67 | 7.90 | 492,119 | -2.32 | -24.52% |
3 Months | 7.89 | 13.70 | 6.67 | 9.53 | 655,505 | -0.75 | -9.51% |
6 Months | 3.26 | 13.70 | 3.14 | 7.55 | 627,352 | 3.88 | 119.02% |
1 Year | 2.68 | 13.70 | 2.43 | 5.57 | 1,015,590 | 4.46 | 166.42% |
3 Years | 11.74 | 33.0975 | 2.25 | 11.38 | 999,475 | -4.60 | -39.18% |
5 Years | 14.50 | 33.0975 | 2.25 | 11.41 | 670,626 | -7.36 | -50.76% |
Fulcrum Therapeutics Description
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. It has developed a proprietary product engine that employs to identify and validate cellular drug targets that can modulate gene expression. Its product candidate, losmapimod, is a small molecule that was developed for the treatment of FSHD, a muscle-wasting disorder that leads to physical impairments and disability. |